Insights
Insights From Our Experts
Articles
From R&D to ROI: AI’s impact on pharma commercialisation
Artificial intelligence (AI) has been a transformative force in the pharmaceutical industry for over a decade. AI can be categorised into two distinct types: “left-brain AI” and “right-brain AI.” The former, also known as classical AI,…
Successfully Navigating Global Commercialization- A View from the C-Suite and Global Commercial Leaders
Launching in today’s unpredictable market is a journey with new challenges around every corner. While product pipelines are rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build…
Patient Centric 3.0: Why a Direct-to-Patient Model Is a Game Changer
At the Frontiers Health 2024 event, Scott Snyder, EVERSANA’s Chief Digital Officer, led a panel discussion titled “Patient Centric 3.0: Why a Direct-to-Patient Model Is a Game Changer,” where industry experts explained the transformative impact of…
From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services
Navigating the healthcare system can be enormously challenging for patients, who often face numerous obstacles that hinder their access to quality care. Common barriers include financial constraints, long wait times, socio-economic disparities, fragmented care coordination, among…
Insight from Frontiers Health: Harnessing Machine Learning to Transform Clinical Outcomes
Our Chief Medical Officer, Dr. Pierantonio Russo, joined on stage at Frontiers Health 2024 to discuss the impact of Machine Learning (ML) on healthcare, particularly in predicting hospital readmissions and managing chronic diseases. In this session,…
The Promise of Direct-to-Patient – What’s Really Needed for Patient Access
In today’s healthcare landscape, patients are no longer passive recipients of care. They are empowered, tech-savvy stakeholders who demand efficiency and transparency. Yet, despite advancements in consumer innovation, the healthcare system often leaves them frustrated with…
The Importance of Quality-of-Life Metrics in mCRPC
Posted by
Rhett Figliuzzi , Samantha Craigie , Sarah Walsh , Imtiaz Samjoo on November 26, 202411/26/24
Prostate cancer is one of the most diagnosed malignancies in the world, with many patients progressing to an advanced stage of the disease called metastatic castration-resistant prostate cancer (mCRPC). Due to the poor prognosis and incurable…
What’s Holding Back AI Adoption? Three Insights from Recent Study
Artificial Intelligence (AI) continues to change at warp speed, creating a “pull” versus “push” customer engagement model where a growing percentage of people ‘pull’ the information they want today from platforms like ChatGPT or Claude, making…
The Increasing Role of AI in Improving the Diagnostic Imaging Landscape
Discover how artificial intelligence is revolutionizing the medical imaging landscape in our latest white paper, “The Increasing Role of AI in Improving the Diagnostic Imaging Landscape.” This comprehensive guide explores: Enhanced Diagnostic Accuracy: Learn how AI…
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs
Posted by
Krista Tantakoun , Christopher Olsen , Fatemeh Mirzayeh Fashami , Imtiaz Samjoo , Chris Cameron, PhD on November 19, 202411/19/24
The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan…